Propranolol for the treatment of orbital infantile hemangiomas

Ophthalmic Plastic and Reconstructive Surgery

Volumn 27, Issue 3, 2011, Pages 190-194

  Fridman, Gretta ^a   Grieser, Eric ^b   Hill, Robert ^c   Khuddus, Nausheen ^b   Bersani, Tom ^c   Slonim, Charles ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; PREDNISONE; PROPRANOLOL; TRIAMCINOLONE;

AMBLYOPIA; ARTICLE; ASTIGMATISM; CAPILLARY HEMANGIOMA; CHILDHOOD CANCER; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CUSHINGOID SYNDROME; DRUG DOSE INCREASE; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; EYE MOVEMENT; EYE REFRACTION; EYELID; FEMALE; HUMAN; INFANT; MALE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PTOSIS; RECURRENCE RISK; RETROSPECTIVE STUDY; TELEMETRY; TREATMENT DURATION; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VOLUME;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; ANTINEOPLASTIC AGENTS; FEMALE; HEMANGIOMA, CAPILLARY; HUMANS; INFANT; INFANT, NEWBORN; MALE; ORBITAL NEOPLASMS; PROPRANOLOL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79957853888     PISSN: 07409303     EISSN: 15372677     Source Type: Journal    
DOI: 10.1097/IOP.0b013e318201d344     Document Type: Article

References (32)

1. Frieden IJ, Haggstrom AN, Drolet BA, et al. Infantile hemangiomas: current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas, April 7-9, 2005, Bethesda, Maryland, USA. Pediatr Dermatol 2005;22:383-406. (Pubitemid 43960991)
2. Stal S, Hamilton S, Spira M. Hemangiomas, lymphangiomas, and vascular malformations of the head and neck. Otolaryngol Clin North Am 1986;19:769-96. (Pubitemid 17192955)
3. Jacobs AH, Walton RG. The incidence of birthmarks in the neonate. Pediatrics 1976;58:218-22.
4. Kleinman ME, Greives MR, Churgin SS, et al. Hypoxia-induced mediators of stem/progenitor cell trafficking are increased in children with hemangioma. Arterioscler Thromb Vasc Biol 2007;27:2664-70. (Pubitemid 350158920)
5. Barnés CM, Huang S, Kaipainen A, et al. Evidence by molecular profiling for a placental origin of infantile hemangioma. Proc Natl Acad Sci U S A 2005;102:19097-102. (Pubitemid 43049572)
6. North PE, Waner M, Brodsky MC. Are infantile hemangiomas of placental origin? Ophthalmology 2002;109:633-4. (Pubitemid 34270116)
7. Pittman KM, Losken HW, Kleinman ME, et al. No evidence for maternal-fetal microchimerism in infantile hemangioma: a molecular genetic investigation. J Invest Dermatol 2006;126:2533-8. (Pubitemid 44582274)
8. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008;358:2649-51. (Pubitemid 351831393)
9. Sans V, De La Roque ED, Berge J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics 2009;124; e423-31.
10. Taban M, Goldberg RA. Propranolol for orbital hemangioma. Ophthalmology 2010;117:195.
11. Fay A, Nguyen J, Jakobiec FA, et al. Propranolol for isolated orbital infantile hemangioma. Arch Ophthalmol 2010;128:256-8.
12. Pandey A, Gangopadhyay A, Gopal S, et al. Twenty years experience of steroids in infantile hemangioma-a developing country's perspective. J Pediatr Surg 44:688-94.
13. Haggstrom A, Drolet B, Baselga E, et al. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr 150:291-4.
14. Bruckner AL, Frieden IJ. Hemangiomas of infancy. J Am Acad Dermatol 2003;48:477-93; quiz 494-6. (Pubitemid 36397008)
15. Drolet BA, Esterly NB, Frieden IJ. Hemangiomas in children. N Engl J Med 1999;341:173-81. (Pubitemid 29325746)
16. Esterly NB. Cutaneous hemangiomas, vascular stains and malformations, and associated syndromes. Curr Probl Pediatr 1996;26:3.
17. Enjolras O, Gelbert F. Superficial hemangiomas: associations and management. Pediatr Dermatol 1997;14:173-9. (Pubitemid 27255859)
18. Stigmar G, Crawford JS, Ward CM, Thomson HG. Ophthalmic sequelae of infantile hemangiomas of the eyelids and orbit. Am J Ophthalmol 1978;85:806-13. (Pubitemid 8350239)
19. Robb RM. Refractive errors associated with the eyelids and orbit in infancy, Am J Ophthalmol 1977;83:52-8. (Pubitemid 8025659)
20. Chiller KG, Passaro D, Frieden IJ. Hemangiomas of infancy: clinical characteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex. Arch Dermatol 2002;138:1567-76. (Pubitemid 35453469)
21. Haggstrom AN, Drolet BA, Baselga E, et al. Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics 2006;118:882-887. (Pubitemid 46091612)
22. Chang LC, Haggstrom AN, Drolet BA, et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics 2008;122:360-7.
23. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992;326:1456-63.
24. Nguyen J, Fay A. Pharmacologic therapy for periocular infantile hemangiomas: a review of the literature. Semin Ophthalmol 2009;24:178-84.
25. Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg 1999;104:1616-23. (Pubitemid 29510480)
26. Bauman NM, Burke DK, Smith RJ. Treatment of massive or life-threatening hemangiomas with recombinant alpha (2a)-interferon. Otolaryngol Head Neck Surg 1997;117:99-110. (Pubitemid 27304879)
27. Adams D, Orme L, Bowers D. Vincristine treatment for complicated hemangiomas. Abstract presented at the 14th International Workshop on Vascular Anomalies, Nijmegen, The Netherlands, June 28, 2002.
28. Martinez MI, Sanchez-Carpintero I, North PE, Mihm MC Jr. Infantile hemangioma: clinical resolution with 5% imiquimod cream. Arch Dermatol 2002;138:881-4. (Pubitemid 34700733)
29. Graceway Pharmaceuticals, Inc., Somerville, NJ, U. S. A. Aldara prescribing information.
30. Siegfried EC, Keenan WJ, Al-Jureidini S. More on propranolol for hemangiomas of infancy. N Engl J Med 2008;359:2846-7.
31. D'Angelo G, Lee H, Weiner RI. cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation. J Cell Biochem 1997;67:353-66. (Pubitemid 27509471)
32. Sommers Smith SK, Smith DM. Beta blockade induces apoptosis in cultured capillary endothelial cells. In Vitro Cell Dev Biol Anim 2002;38:298-304. (Pubitemid 35204978)